DAPAgliflozin for renal protection in heart transplant recipients. Rationale and design of the randomized controlled DAPARHT trial
Oscar Ö. Braun, Lars Gullestad, Kaspar Broch, Elisabeth Bjørkelund et al.
Citations
1 citations
Journal
American Heart Journal
Topics
Renal Transplantation Outcomes and Treatments
Field-Weighted Citation Impact (FWCI)
1.99
article
DAPAgliflozin for renal protection in heart transplant recipients. Rationale and design of the randomized controlled DAPARHT trial
Oscar Ö. Braun, Lars Gullestad, Kaspar Broch, Elisabeth Bjørkelund, Håvard Ravnestad, Olivier C. Manintveld, Ida Haugen Löfman, Kevin Damman, Mariusz K. Szymanski, Stine Holmen
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
American Heart JournalVol. 291
Institutions
Oslo University Hospital (NO), University Medical Center Groningen (NL), Karolinska University Hospital (SE), University of Groningen (NL), University of Oslo (NO), Lund University (SE), Innlandet Hospital Trust (NO), Erasmus MC (NL), University Medical Center Utrecht (NL), Skåne University Hospital (SE)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
DAPAgliflozin for renal protection in heart transplant recipients. Rationale and design of the randomized controlled DAPARHT trial — Oscar Ö. Braun, Lars Gullestad, et al. · American Heart Journal (2025) | TGRS Research Map | TGRS